Ceftriaxone Sodium+ Tazobactam Sodium in pharma franchise in Punjab

Ceftriaxone Sodium+ Tazobactam Sodium in PCD pharma franchise in Bengaluru

Ceftriaxone Sodium+ Tazobactam Sodium in top pharma company in Howrah

Ceftriaxone Sodium+ Tazobactam Sodium in pcd pharma supplier in Ranchi

Ceftriaxone Sodium+ Tazobactam Sodium in phama franchise company in India
Ceftriaxone Sodium+ Tazobactam Sodium in phama distributor in Jabalpur

Home/Products /ceftriaxone-1000mg-tazobactum-125mg-injection

Fritcet TZ 1.125 Injection

Composition : Ceftriaxone Sodium I.P. 1000mg + Tazobactam Sodium I.P. 125mg

Dosage Form : Injection

Packaging Type : Vial + Water

Packaging : Mono

Price : ₹186/-

Fritcet TZ 1.125 Injection is a potent combination antibiotic that merges the efficacy of Ceftriaxone, a third-generation cephalosporin, with Tazobactam, a beta-lactamase inhibitor. This combination is specifically designed to combat severe bacterial infections caused by beta-lactamase-producing organisms that are resistant to conventional antibiotics.

Ceftriaxone works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death, while Tazobactam enhances its activity by neutralizing the resistance mechanisms of beta-lactamase enzymes. This dual-action makes the injection highly effective against a broad spectrum of Gram-positive and Gram-negative bacteria.

Fritcet TZ is widely prescribed for treating complicated intra-abdominal infections, skin and soft tissue infections, respiratory tract infections, urinary tract infections, and septicemia. It is also beneficial in cases where other antibiotics fail due to resistance.

Read More

About the Product

Fritcet TZ 1.125 Injection is a potent combination antibiotic that merges the efficacy of Ceftriaxone, a third-generation cephalosporin, with Tazobactam, a beta-lactamase inhibitor. This combination is specifically designed to combat severe bacterial infections caused by beta-lactamase-producing organisms that are resistant to conventional antibiotics.

Ceftriaxone works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death, while Tazobactam enhances its activity by neutralizing the resistance mechanisms of beta-lactamase enzymes. This dual-action makes the injection highly effective against a broad spectrum of Gram-positive and Gram-negative bacteria.

Fritcet TZ is widely prescribed for treating complicated intra-abdominal infections, skin and soft tissue infections, respiratory tract infections, urinary tract infections, and septicemia. It is also beneficial in cases where other antibiotics fail due to resistance.

Common side effects may include diarrhea, rash, and changes in liver function tests. Severe allergic reactions and Clostridium difficile-associated diarrhea have been reported.

Used to treat severe bacterial infections, including those caused by beta-lactamase-producing organisms.

Consult a healthcare professional before use. Administer only under medical supervision, particularly in cases of renal impairment or known allergies to beta-lactam antibiotics. Fritcet TZ 1.125 Injection is an important therapeutic option in combating bacterial infections. Its dual-action mechanism not only helps to control infection effectively but also addresses the challenge of antibiotic resistance. Always adhere to prescribed dosages and treatment duration to optimize the therapeutic benefits while minimizing potential adverse effects. Regular monitoring during treatment is advised to detect any side effects early, ensuring patient safety and effective management of the infection.

Store at room temperature, away from light and moisture. Ensure that the solution is protected from freezing.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation